Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
J Thromb Haemost ; 22(7): 1847-1856, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38580096

RESUMO

BACKGROUND: The effect of the vitamin K antagonist acenocoumarol on coagulation needs to be reversed when patients undergo an invasive procedure with considerable bleeding risk. A strategy to achieve this is by administering oral vitamin K before a procedure while continuing acenocoumarol. OBJECTIVES: To assess the effect on periprocedural international normalized ratio (INR) values and safety using oral vitamin K as anticoagulant reversal method. METHODS: In this prospective cohort study, consecutive patients using acenocoumarol undergoing elective procedures between 2019 and 2022 were included. According to standard of care in our hospital, patients took 10 mg oral vitamin K 36 to 48 hours before the procedure while continuing their normal use of acenocoumarol. Effectiveness to lower INR to <1.8 preprocedural was assessed. Bleeding and thrombotic complications within 30 days after the procedure were assessed. Periprocedural course of INR was monitored by collecting additional blood samples. RESULTS: Seventy-four patients were included for analysis. On the day of the procedure, an adequate INR of <1.8 was achieved in 99% of patients. One clinically relevant nonmajor bleeding complication and no thrombotic complications were observed during the first 30 days after the procedure. INR gradually restored to therapeutic level during the days after the procedure. CONCLUSION: Using oral vitamin K while patients continue acenocoumarol intake is an effective way to adequately lower INR before an invasive procedure. Low amount of bleeding complications and absence of thromboembolic complications suggest that this is a safe strategy. The INR values returned gradually to therapeutic range after the procedure, probably contributing to the observed low bleeding rate.


Assuntos
Acenocumarol , Anticoagulantes , Coagulação Sanguínea , Coeficiente Internacional Normatizado , Vitamina K , Humanos , Acenocumarol/administração & dosagem , Acenocumarol/efeitos adversos , Vitamina K/antagonistas & inibidores , Estudos Prospectivos , Anticoagulantes/administração & dosagem , Anticoagulantes/efeitos adversos , Idoso , Feminino , Masculino , Coagulação Sanguínea/efeitos dos fármacos , Pessoa de Meia-Idade , Administração Oral , Idoso de 80 Anos ou mais , Hemorragia/induzido quimicamente , Resultado do Tratamento , Procedimentos Cirúrgicos Eletivos , Fatores de Tempo , Monitoramento de Medicamentos/métodos , Esquema de Medicação
2.
Lancet Neurol ; 2024 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-38763149

RESUMO

BACKGROUND: Intravenous thrombolysis is contraindicated in patients with ischaemic stroke with blood pressure higher than 185/110 mm Hg. Prevailing guidelines recommend to actively lower blood pressure with intravenous antihypertensive agents to allow for thrombolysis; however, there is no robust evidence for this strategy. Because rapid declines in blood pressure can also adversely affect clinical outcomes, several Dutch stroke centres use a conservative strategy that does not involve the reduction of blood pressure. We aimed to compare the clinical outcomes of both strategies. METHODS: Thrombolysis and Uncontrolled Hypertension (TRUTH) was a prospective, observational, cluster-based, parallel-group study conducted across 37 stroke centres in the Netherlands. Participating centres had to strictly adhere to an active blood-pressure-lowering strategy or to a non-lowering strategy. Eligible participants were adults (≥18 years) with ischaemic stroke who had blood pressure higher than 185/110 mm Hg but were otherwise eligible for intravenous thrombolysis. The primary outcome was functional status at 90 days, measured using the modified Rankin Scale and assessed through telephone interviews by trained research nurses. Secondary outcomes were symptomatic intracranial haemorrhage, the proportion of patients treated with intravenous thrombolysis, and door-to-needle time. All ordinal logistic regression analyses were adjusted for age, sex, stroke severity, endovascular thrombectomy, and baseline imbalances as fixed-effect variables and centre as a random-effect variable to account for the clustered design. Analyses were done according to the intention-to-treat principle, whereby all patients were analysed according to the treatment strategy of the participating centre at which they were treated. FINDINGS: Recruitment began on Jan 1, 2015, and was prematurely halted because of a declining inclusion rate and insufficient funding on Jan 5, 2022. Between these dates, we recruited 853 patients from 27 centres that followed an active blood-pressure-lowering strategy and 199 patients from ten centres that followed a non-lowering strategy. Baseline characteristics of participants from the two groups were similar. The 90-day mRS score was missing for 15 patients. The adjusted odds ratio (aOR) for a shift towards a worse 90-day functional outcome was 1·27 (95% CI 0·96-1·68) for active blood-pressure reduction compared with no active blood-pressure reduction. 798 (94%) of 853 patients in the active blood-pressure-lowering group were treated with intravenous thrombolysis, with a median door-to-needle time of 35 min (IQR 25-52), compared with 104 (52%) of 199 patients treated in the non-lowering group with a median time of 47 min (29-78). 42 (5%) of 852 patients in the active blood-pressure-lowering group had a symptomatic intracranial haemorrhage compared with six (3%) of 199 of those in the non-lowering group (aOR 1·28 [95% CI 0·62-2·62]). INTERPRETATION: Insufficient evidence was available to establish a difference between an active blood-pressure-lowering strategy-in which antihypertensive agents were administered to reduce blood pressure below 185/110 mm Hg-and a non-lowering strategy for the functional outcomes of patients with ischaemic stroke, despite higher intravenous thrombolysis rates and shorter door-to-needle times among those in the active blood-pressure-lowering group. Randomised controlled trials are needed to inform the use of an active blood-pressure-lowering strategy. FUNDING: Fonds NutsOhra.

3.
J ECT ; 28(1): 64-5, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22343586

RESUMO

Electroconvulsive therapy (ECT) is mainly used for treating severe depression, mania, schizophrenia, and catatonia. Electroconvulsive therapy is usually without serious adverse effects. Headache is a common complaint after ECT but is usually mild and short lasting. Recurrent common migraine induced by ECT has been rarely reported. We report a patient with ECT-induced migraine successfully treated with valproic acid.


Assuntos
Eletroconvulsoterapia/efeitos adversos , GABAérgicos/uso terapêutico , Enxaqueca com Aura/tratamento farmacológico , Enxaqueca com Aura/etiologia , Ácido Valproico/uso terapêutico , Idoso de 80 Anos ou mais , Transtorno Depressivo Maior/complicações , Transtorno Depressivo Maior/terapia , Humanos , Masculino , Exame Neurológico , Tremor/complicações , Vertigem/complicações , Vertigem/tratamento farmacológico
4.
Ann Med ; 54(1): 2770-2776, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36269009

RESUMO

OBJECTIVE: The gold standard for diagnosis of giant cell arteritis (GCA) is a temporal artery biopsy (TAB). We sought for a clinical useful model to predict when an invasive TAB is not necessary to confirm GCA. METHODS: A prospective cohort study was conducted with patients > 50 years with possible GCA, presenting with newly onset headache and/or visual loss. Demographical, clinical, laboratory findings and histological data were collected. RESULTS: Fifty-six (70%) of the 94 patients showed 1 or more halos of the superficial temporal artery branches. Ultrasound-guided biopsy was positive in 28 patients (30%). Four independent variables predicted a positive TAB: weight loss, bilateral headache, positive halo sign and thrombocytosis. The ROC of the model had an area under the curve of 0.932 with a PPV of 83% and a NPV of 94%. CONCLUSIONS: Weight loss, bilateral headache, a positive halo sign with duplex and thrombocytosis are the most important clinical and laboratory predictors for GCA in a selected group of patients. SIGNIFICANCE: In patients > 50 years presenting with new onset headache or visual loss with 3 or more of the above mentioned risk factors, a biopsy of the temporal artery is not needed to confirm the diagnosis GCA.KEY MESSAGESIn our study biopsy of the temporal artery was positive in 30% of the patients with possible GCAWeight loss, bilateral headache, a positive halo sign on duplex and thrombocytosis are predictors for GCAThe halo sign had a high sensitivity but a low specificity for a biopsy proven GCA.


Assuntos
Arterite de Células Gigantes , Trombocitose , Humanos , Arterite de Células Gigantes/complicações , Arterite de Células Gigantes/diagnóstico , Arterite de Células Gigantes/patologia , Estudos Prospectivos , Sensibilidade e Especificidade , Cefaleia/etiologia , Biópsia , Redução de Peso , Estudos Retrospectivos
6.
BMJ Case Rep ; 20142014 Mar 03.
Artigo em Inglês | MEDLINE | ID: mdl-24591382

RESUMO

Ischaemic stroke as the initial presentation of systemic malignancy is reported infrequently and is characterised by ischaemic lesions that exceed the vascular territory of a single vessel. There is also a high rate of early stroke recurrence. Several pathophysiological mechanisms are known to cause cerebrovascular complications in malignancies, as a direct effect of the tumour, paraneoplastic or even of the tumour treatment itself. Prognosis is reportedly poor, treatment is symptomatic and at best anecdotal. We present a case report and available literature.


Assuntos
Adenocarcinoma/diagnóstico , Células Neoplásicas Circulantes , Neoplasias Ovarianas/diagnóstico , Acidente Vascular Cerebral/etiologia , Adenocarcinoma/complicações , Evolução Fatal , Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias Ovarianas/complicações , Acidente Vascular Cerebral/diagnóstico
7.
Front Neurol ; 5: 241, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25484876

RESUMO

Recent studies suggest that migraine may be associated with gastrointestinal (GI) disorders, including irritable bowel syndrome (IBS), inflammatory bowel syndrome, and celiac disease. Here, an overview of the associations between migraine and GI disorders is presented, as well as possible mechanistic links and clinical implications. People who regularly experience GI symptoms have a higher prevalence of headaches, with a stronger association with increasing headache frequency. Children with a mother with a history of migraine are more likely to have infantile colic. Children with migraine are more likely to have experienced infantile colic compared to controls. Several studies demonstrated significant associations between migraine and celiac disease, inflammatory bowel disease, and IBS. Possible underlying mechanisms of migraine and GI diseases could be increased gut permeability and inflammation. Therefore, it would be worthwhile to investigate these mechanisms further in migraine patients. These mechanisms also give a rationale to investigate the effects of the use of pre- and probiotics in migraine patients.

8.
BMJ Case Rep ; 20132013 Mar 20.
Artigo em Inglês | MEDLINE | ID: mdl-23519507

RESUMO

Various nerve anastomoses and anatomic variants in the nervous system have been described. It is important to be familiar with these anastomoses because they can mimic several clinical conditions, possibly leading to misdiagnosis. We report the case of a patient who experienced progressive loss of strength in his left hand without sensory complaints. On neurological examination atrophy was seen in the thenar and first dorsal interosseous muscles of the left hand. Serial electrophysiological studies ruled out motor neuron disease. Electromyography and nerve conduction studies revealed a Riche-Cannieu anastomosis in the left hand. In combination with piso-hamate hiatus syndrome, this anastomosis explained the clinical condition of the patient. It is important to be aware of this anastomosis and this syndrome because it can mimic motor neuron disease.


Assuntos
Nervo Mediano/anormalidades , Doenças do Sistema Nervoso Periférico/complicações , Doenças do Sistema Nervoso Periférico/diagnóstico , Nervo Ulnar/anormalidades , Humanos , Masculino , Doenças do Sistema Nervoso Periférico/fisiopatologia , Síndrome , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA